Institutional investors purchased a net $1.1 million shares of THRX during the quarter ended December 2013. This may signal that the smart money is gaining interest in this company as the 75.01% of the shares outstanding that institutional investors hold is among the lowest in the Biotechnology industry.
Mutual fund holders
Largest Quarterly Institutional Transactions
Latest Institutional Activity
THE BAUPOST GROUP LLC Bought 1.6 Million shares of Theravance Inc
IRIDIAN ASSET MANAGEMENT LLC Bought 1.2 Million shares of Theravance Inc